

# **ANGIOMA ALLIANCE**

Presents the 15th Annual

# CCM SCIENTIFIC MEETING

THE DOUBLETREE BY HILTON HOTEL SILVER SPRING, MD

November 7-8, 2019

# Day 1 | Thursday, November 7th, 2019

- 7:30 Registration, Pinnacle Grand Ballroom Foyer
- 7:30 Continental Breakfast, Connection Room
- 8:30 Welcome & Opening Remarks, Pinnacle Grand Ballroom

### SESSION I - ANIMALS & PRECLINICAL STUDIES

Moderated by TBD

- 8:40 Understanding the role of CCM3 in endothelial development and disease Tvisha Misra Sickkids Hospital
- 9:00 Specific deletion of CCM3 in brain endothelium reliably models human cerebral cavernous malformations

  Huanjiao Jenny Zhou Yale
- 9:20 Advancing CCM mouse models for pre-clinical therapeutic testing Matthew Detter Duke University
- 9:40 Transcriptomes of Cerebral Cavernous Angiomas Clarify Mechanisms of Lesion Genesis and Maturation in Murine Pre-Clinical Models and Human Symptomatic Hemorrhage Romuald Girard University of Chicago
- 10:00 Discussion
- 10:20 Break

#### Session II - Natural History & Biomarkers

Moderated by TBD

- 10:40 Angioma Alliance updates patient engagement, international collaborations & unraveling the genealogy of an American founder mutation

  Connie Lee Angioma Alliance
- 11:00 Health-related Quality of Life in Cavernous Angioma Patients with Symptomatic Hemorrhage

Helen Kim • UCSF

- 11:20 Subclinical Imaging Changes in Cerebral Cavernous Angiomas During Prospective
  Surveillance
  - Julian Carrion-Penagos University of Chicago
- 11:40 Common transcriptomic and biomarker signatures in the aging brain and in Mendelian neurovascular disease, cerebral cavernous malformation Issam Awad University of Chicago
- 12:00 Discussion
- 12:20 LUNCH CONNECTION

#### SESSION III - HEMORRHAGE RISK & CLINICAL TRIALS

Moderated by TBD

- 1:30 Predictors of Intracranial hemorrhage in Familial Cerebral Cavernous Malformation Patients - BVMC Study Cohort Atif Zafar • UNM
- 1:50 Predictors of Initial Presentation with Hemorrhage in Patients with Cavernous Malformations the role of clinical history and medications

  Kelly Flemming Mayo Clinic
- 2:10 Association between statin or beta blocker drug use and hemorrhage from cerebral cavernous malformations
  Susanna Zuurbier Amsterdam University
- 2:30 TREAT\_CCM A multicenter randomized clinical trial on propranolol in familial cerebral cavernous malformations
  Roberto Latini Istituto Mario Negri
- 2:50 Tempol clinical trials and developing a CCM-Health Index Tracey Clayton Recursion Pharmaceuticals
- 3:10 DISCUSSION
- **3:30 GROUP PHOTO**

# POSTER SESSION | DISCOVERY ROOM (3:45-5 PM)

Symptomatic Brain Hemorrhages from Cavernous Angioma Following Botulinum Toxin Injections, and Suggested TLR/MEKK3 Mechanism Julian Carrion-Penagos • University of Chicago

Characterizing Meningeal Lymphatic Development in Zebrafish Daniel Castranova • NIH

The Cavernous Angioma Patient Registry – a tool for research & recruitment Kristen Dahlem • Angioma Alliance

nfatc1 deficiency causes thoracic duct dilation during vascular development Alexandra Fister • NICHD/NIH

Affected health domains in patients with brainstem cavernous malformations Kelly Flemming • Mayo Clinic

Artery/Vein Plasticity After Vessel Injury Leah Greenspan • NIH

Target sequencing for germline mutations in sporadic CCM patients Hiroki Hongo • University of Tokyo

*CCM1* and *CCM3* cooperate to maintain intestinal function in *C. elegans* Sam Krempel • SickKids Hospital

The role of CCM-3 in the ERK-5 pathway

Ben Lant • SickKids Hospital

Selective ROCK Inhibitors Ameliorate CCM Lesions in an Acute Mouse Model Matthew Lee • Cervello Therapeutics

Endothelial cell clonal expansion in the development of Cerebral Cavernous Malformations

Matteo Malinverno • FIRC Institute

Female Hormonal Therapy and Cavernous Angioma Hemorrhage Jorge Marcondes • Universidade Federal Rio de Janeiro

Variants in Inflammation-Related Genes Plus DNA Repair Enzymes and Aggressiveness in a CCM3 Brazilian Patient with Cerebral Cavernous Malformations.

Jorge Marcondes • Universidade Federal Rio de Janeiro

KRIT1 deficiency promotes aortic endothelial dysfunction and atherosclerosis Andrea Perrelli • University of Torino

The role of MRCK-1 in biological tube development

Evelyn Popiel • The Hospital for Sick Children

Adapting BioID for Use in Zebrafish to Investigate the Protein-Protein Interactions of CCM3

Shimon Rosenthal • University of Toronto

A Brain Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease

Robert Shenkar • University of Chicago

Studying the origin and function of novel vascular-associated cells in the zebrafish meninges

Marina Venero Galanternik • NIH

Characterizing Novel RHOA Mutant Alleles and their Effects on Vascular Integrity Joseph Yano • NIH

Prevalence of Obstructive Sleep Apnea (OSA) in Cerebral Cavernous Malformations Atif Zafar • University of New Mexico

Autoantigen(s) Trigger a Robust Immune Response in Cerebral Cavernous Malformations

Dondong Zhang & Abhinav Srinath • University of Chicago

5:00 Break

# WELCOME DINNER | MRS. K'S RESTAURANT & CELLAR (7-9 PM)

9201 Colesville Road, Silver Spring, MD

# Day 2 | Friday, November 8th, 2019

#### CONCURRENT SESSION SCIENTIFIC MEETING & FAMILY CONFERENCE

- 7:30 Continental Breakfast, Connection Room
- 8:30 Welcome & Introduction, Pinnacle Ballroom
- 8:40 PLENARY PRESENTATION

Keynote Address to Patients, Families, and Investigators: Milestones and Our Road Ahead

Issam Awad • University of Chicago

9:30 Break

## Session IV - Vascular Biology & Lesion Development

Moderated by TBD

9:50 Characterizing the function of RHOA in regulating vascular development and integrity in vivo

Laura Pillay, NICHHD/NIH

10:10 Blood flow suppresses vascular anomalies in zebrafish model of cerebral cavernous malformations

Claudia Rodel - Potsdam University

10:30 Axonal Guidance Factors Regulate Invasion and Migration of Brain Endothelial Cells in Normal Development and Cerebrovascular Malformations Katie Fehnel - Boston Children's

10:50 Discussion

#### 11:45 Lunch - Connection with Family Conference Attendees

## SESSION V - VASCULAR DEVELOPMENT & LESION GENESIS

Moderated by TBD

- 1:00 *CCM3*, a protein mutated in cerebral cavernous malformations, is a signal transduction adapter

  Kento Abe University of Toronto
- 1:20 Alternatively spliced isoforms reveal a novel type of PTB domain in CCM2 protein Jun Zhang Texas Tech University
- 1:40 NgBR Regulates the Expression of CCM1/2 in Endothelial Cells via Histone Acetylation Zhi Fang New York University
- 2:00 Ccm2l deletion aggravates cerebral cavernous malformation in Ccm2-deficient mice by activating MEKK3-KLF signaling pathway
  [aesung Choi Centenary Institute]
- 2:20 Pharmacological inhibition of the HEG1-KRIT1 protein complex increases Kruppel-like Factors 4 and 2 expression in endothelial cells.

  Miguel Lopez-Ramirez UCSD
- 2:40 DISCUSSION
- 3:00 Break with Family Conference
- 3:15 CLOSE OF MEETING

# Thank you to our sponsors!





DISEASE PREVENTION THROUGH GENETIC TESTING